Brief: VBL Therapeutics Announces Top-Line Data From Phase 3 Oval Trial Of Ofra-Vec

Notable Labs

19/07/2022 21:38

July 19 (Reuters) - Vascular Biogenics Ltd  VBLT.O :
    * VBL THERAPEUTICS ANNOUNCES TOP-LINE DATA FROM PHASE 3 OVAL
TRIAL
OF OFRA-VEC IN PATIENTS WITH PLATINUM-RESISTANT OVARIAN CANCER
    * VBL THERAPEUTICS -TRIAL DID NOT MEET THE PRIMARY ENDPOINTS
OF
ACHIEVING A STATISTICALLY SIGNIFICANT IMPROVEMENT IN PFS OR OS
    * VBL THERAPEUTICS - CONTINUES TO MOVE VB-601 PROGRAM
FORWARD
TOWARDS A FIRST-IN-HUMAN CLINICAL TRIAL, EXPECTED TO BEGIN IN Q4
OF 2022
    * VBL THERAPEUTICS - ANTICIPATES THAT ITS CURRENT CASH ON
HAND
WILL BE SUFFICIENT TO FUND PLANNED OPERATIONS FOR AT LEAST NEXT
12 MONTHS


Further company coverage:  VBLT.O 

 ((Reuters.Briefs@thomsonreuters.com;))